NCT00496158终止3 期
A Multi-Center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Negative Chronic Hepatitis Due to Hepatitis B Virus
Pharmasset129 个研究点 分布在 3 个国家开始时间: 2007年8月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- 试验地点
- 129
研究概览
简要总结
The objectives of this study are to compare in nucleoside treatment-naïve subjects, the efficacy and safety of clevudine 30 mg once daily versus adefovir 10 mg once daily, each as monotherapy, for 48 weeks, 72 weeks, and 96 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Nucleoside treatment-naïve subjects of either gender, females who are non-pregnant and non-lactating, aged 16 years or older (or the legal age of consent as allowed by local regulations), with compensated hepatic function despite a diagnosis of chronic HBeAg negative hepatitis B infection (i.e., based on serological, virological and histological markers) will be eligible for this study.
- •Subjects entering the study with an historical biopsy will have chronic hepatic inflammatory injury at screening (Knodell HAI score ≥ 4 and modified Ishak fibrosis score ≤ 5).
- •The number of subjects entering the study with an Ishak fibrosis score of 5 will be limited to approximately 10%. If applicable, subjects must cease previous treatment with any form of alpha interferon 12 months prior to baseline.
- •For eligibility, subjects must meet the laboratory criteria for total bilirubin, prothrombin time, serum albumin, platelet count, absolute neutrophil count, ANA titer and have a creatinine clearance of ≥ 50 mL/min.
排除标准
- •Subjects participating in a clinical trial or receiving an investigational agent for any reason within 60 days of baseline will be excluded.
- •Subjects with clinically significant concomitant diseases will be excluded.
研究者
研究点 (129)
Loading locations...
相似试验
终止
3 期
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B VirusChronic HepatitisHepatitis BNCT00496002Pharmasset
已完成
3 期
Study Utilizing Rilonacept in Gout ExacerbationsAcute Gout FlareNCT00855920Regeneron Pharmaceuticals225
已完成
3 期
National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple SclerosisMultiple SclerosisNCT02937285Rennes University Hospital35
已完成
2 期
Finafloxacin for the Treatment of cUTI and/or Acute PyelonephritisUrinary Tract InfectionsAcute PyelonephritisNCT01928433MerLion Pharmaceuticals GmbH225
终止
2 期
GSK2251052 in Complicated Urinary Tract InfectionInfections, Urinary TractNCT01381549GlaxoSmithKline20